4-Methyl-1,2,5-triazanaphthalin | 45875-12-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-Methyl-1,2,5-triazanaphthalin
• 英文别名: 4-methyl-pyrido[3,2-c]pyridazine；4-Methylpyrido[3,2-c]pyridazine
• CAS: 45875-12-5
• 化学式: C₈H₇N₃
• 分子量: 145.164
• InChiKey: YQYIGWXHXOBCDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] HERBICIDAL COMPOUNDS<br/>[FR] COMPOSÉS HERBICIDES
  申请人：SYNGENTA CROP PROTECTION AG

  公开号：WO2021058592A1

  公开（公告）日：2021-04-01

  Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

  式（I）中的化合物，其中取代基如权利要求1中定义的那样，作为农药是有用的，特别是作为除草剂。
• Thermally activated delayed fluorescent material based on 9,10-dihydro-9,9-dimethylacridine analogues for prolonging device longevity
  申请人：Arizona Board of Regents

  公开号：US11245078B2

  公开（公告）日：2022-02-08

  Thermally activated delayed fluorescent compounds and uses thereof are described. The thermally activated delayed fluorescent compounds are an analogues of 9,10-dihydro-9,9-dimethylacridine compounds.

  本文描述了热激活延迟荧光化合物及其用途。这些热激活延迟荧光化合物是9,10-二氢-9,9-二甲基蒽嗪化合物的类似物。
• Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US10000487B2

  公开（公告）日：2018-06-19

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A1, A2, A3, A4, W1, W2, Y, X, R1, R2, R3, R4a, R4b, R5a, R5b, R6, R7, R8, R9, R9a, R9b, R10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

  本发明提供了符合式 IA 或式 IB 的化合物及其立体异构体、同系物或药学上可接受的盐的合成、药学上可接受的制剂和用途。 对于式 IA 和式 IB 化合物 A1、A2、A3、A4、W1、W2、Y、X、R1、R2、R3、R4a、R4b、R5a、R5b、R6、R7、R8、R9、R9a、R9b、R10 和下标 n 如说明书中所定义。本发明的式IA和式IB化合物是Mnk的抑制剂，可用于各种治疗应用，包括但不限于炎症和各种癌症的治疗。
• Condensed cyclic compound and organic light emitting device including the same
  申请人：Samsung Electronics Co., Ltd.

  公开号：US10686142B2

  公开（公告）日：2020-06-16

  A condensed cyclic compound represented by Formula 1: wherein in Formula 1, groups and variables are the same as defined in the specification.

  由式 1 表示的缩合环状化合物： 其中，式 1 中的基团和变量与说明书中定义的相同。
• RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20160311871A1

  公开（公告）日：2016-10-27

  An object to be solved by the present invention is to identify patients resistant to known HSP90 inhibitors, and to provide a novel therapeutic agent for treating the patients who have become resistant to known HSP90 inhibitors. As a means for solving the above problems, the present invention provides identification of the patients based on a protein, which is an HSP90 family protein having a mutation in the site corresponding to F138 of HSP90α class A consisting of the amino acid sequence of SEQ ID NO: 1, and use of a substance that inhibits the protein as an active ingredient of a therapeutic agent.